Zamir A, Rasool M, Alqahtani F, Alqhtani H, Ahmad T
Pharmaceutics. 2025; 16(12.
PMID: 39771532
PMC: 11677874.
DOI: 10.3390/pharmaceutics16121553.
Faramarzi F, Shiran M, Rafati M, Farhadi R, Salehifar E, Nakhshab M
Indian J Pharmacol. 2021; 53(2):108-114.
PMID: 34100394
PMC: 8265417.
DOI: 10.4103/ijp.IJP_504_19.
Romandini A, Pani A, Schenardi P, Pattarino G, De Giacomo C, Scaglione F
Antibiotics (Basel). 2021; 10(4).
PMID: 33917430
PMC: 8067449.
DOI: 10.3390/antibiotics10040393.
Wu F, Zhou Y, Li L, Shen X, Chen G, Wang X
Front Chem. 2020; 8:726.
PMID: 33062633
PMC: 7517894.
DOI: 10.3389/fchem.2020.00726.
Rashid M, Sarfraz M, Arafat M, Hussain A, Abbas N, Sadiq M
BMC Pharmacol Toxicol. 2020; 21(1):56.
PMID: 32727574
PMC: 7389632.
DOI: 10.1186/s40360-020-00429-y.
Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration.
Liu X, Dallmann A, Wang Y, Green D, Burnham J, Chiang B
J Clin Pharmacol. 2019; 59(8):1130-1143.
PMID: 30865317
PMC: 6617747.
DOI: 10.1002/jcph.1406.
PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.
Tjollyn H, Vermeulen A, Van Bocxlaer J
AAPS J. 2018; 21(1):8.
PMID: 30498862
DOI: 10.1208/s12248-018-0277-7.
Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.
Vozmediano V, Sologuren A, Lukas J, Leal N, Rodriguez M
Pharm Res. 2017; 34(12):2720-2734.
PMID: 28971281
DOI: 10.1007/s11095-017-2248-6.
Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro M, Gomez M, Kip A, Cossio A, Ortiz E, Navas A
Antimicrob Agents Chemother. 2016; 61(3).
PMID: 27956421
PMC: 5328512.
DOI: 10.1128/AAC.02198-16.
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.
Peigne S, Bouzom F, Brendel K, Gesson C, Fouliard S, Chenel M
J Pharmacokinet Pharmacodyn. 2015; 43(1):13-27.
PMID: 26563503
DOI: 10.1007/s10928-015-9451-z.
Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.
Donovan M, Boylan G, Murray D, Cryan J, Griffin B
Br J Clin Pharmacol. 2015; 81(1):62-77.
PMID: 26302437
PMC: 4693568.
DOI: 10.1111/bcp.12753.
Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants.
Emoto C, Fukuda T, Johnson T, Adams D, Vinks A
CPT Pharmacometrics Syst Pharmacol. 2015; 4(2):e17.
PMID: 26225230
PMC: 4360665.
DOI: 10.1002/psp4.17.
Developmental pharmacokinetics in pediatric populations.
Lu H, Rosenbaum S
J Pediatr Pharmacol Ther. 2015; 19(4):262-76.
PMID: 25762871
PMC: 4341411.
DOI: 10.5863/1551-6776-19.4.262.
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Tay-Sontheimer J, Shireman L, Beyer R, Senn T, Witten D, Pearce R
Pharmacogenomics. 2014; 15(16):1947-62.
PMID: 25521354
PMC: 4486214.
DOI: 10.2217/pgs.14.155.
Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.
Tjollyn H, Snoeys J, Colin P, Van Bocxlaer J, Annaert P, Cuyckens F
Pharm Res. 2014; 32(1):260-74.
PMID: 25048637
DOI: 10.1007/s11095-014-1460-x.
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
Khalil F, Laer S
AAPS J. 2014; 16(2):226-39.
PMID: 24399240
PMC: 3933580.
DOI: 10.1208/s12248-013-9555-6.
Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.
Huisinga W, Solms A, Fronton L, Pilari S
CPT Pharmacometrics Syst Pharmacol. 2013; 1:e4.
PMID: 23835884
PMC: 3603474.
DOI: 10.1038/psp.2012.3.
A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.
Encinas E, Calvo R, Lukas J, Vozmediano V, Rodriguez M, Suarez E
Paediatr Drugs. 2013; 15(3):247-57.
PMID: 23657896
DOI: 10.1007/s40272-013-0029-1.
Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
Jones H, Mayawala K, Poulin P
AAPS J. 2012; 15(2):377-87.
PMID: 23269526
PMC: 3675752.
DOI: 10.1208/s12248-012-9446-2.
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C, Mentre F, Gaynor C, Brendel K, Gesson C, Chenel M
Clin Pharmacokinet. 2012; 52(1):43-57.
PMID: 23212609
DOI: 10.1007/s40262-012-0022-9.